Advertisement

Malignant Intrarenal/Renal Pelvis Paraganglioma with Co-Occurring SDHB and ATRX Mutations

  • Trent IrwinEmail author
  • Eric Q. Konnick
  • Maria S. Tretiakova
Article
  • 3 Downloads

Abstract

Paragangliomas are rare neuroendocrine tumors which originate from embryonic neural crest cells. These tumors may arise from parasympathetic or sympathetic paraganglia, may secrete catecholamines, and can occur in varied anatomic locations, with some locations being less common than others. Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas and pheochromocytomas and have been associated with germline heterozygous mutations in MAX, SDHA, SDHAF2, SDHB, SDHC, SDHD, or TMEM127. Herein, we report a case of a middle-aged male who was diagnosed with an intrarenal/renal pelvis paraganglioma after presenting in hypertensive crisis with palpitations, headache, and diaphoresis. He was later found to have extensive metastatic disease, as well as genetic testing that showed biallelic inactivation of SDHB and a co-occurring somatic ATRX mutation. Respectively, these germline and somatic mutations have been associated with increased risk of metastatic spread and clinical aggressiveness. Despite multiple surgical resections and various treatment modalities, the patient eventually elected for palliative care measures and died of disease. Together, the findings seen in this patient are unique and serve as an appropriate catalyst for discussing the unusual locations, interesting genetic profiles, and metastatic risk factors that may be associated with paragangliomas.

Keywords

Paraganglioma Metastatic SDHB ATRX Intrarenal/renal pelvis 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Supplementary material

12022_2019_9594_MOESM1_ESM.pptx (1.1 mb)
ESM 1 (PPTX 1145 kb)

References

  1. 1.
    Lloyd, R. V., Osamura, R. Y., Klöppel, G., & Rosai, J. (2017). WHO classification of tumours of endocrine organs. Lyon: International Agency for Research on Cancer.Google Scholar
  2. 2.
    Asa, S., Ezzat, S., & Mete, O. (2018). The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. Journal of Clinical Medicine, 7(280).  https://doi.org/10.3390/jcm7090280 CrossRefGoogle Scholar
  3. 3.
    Yi, C., Han, L., Yu, J. (2017). Paraganglioma of the renal pelvis: A case report and review of literature. Tumori, 103, S47-S49.  https://doi.org/10.5301/tj.5000677 CrossRefGoogle Scholar
  4. 4.
    Yamamoto, N., Maeda, S., & Mizoguchi, Y. (2007). Malignant paraganglioma arising from the kidney. International Journal of Clinical Oncology, 12(2), 160-162.  https://doi.org/10.1007/s10147-006-0632-z CrossRefPubMedGoogle Scholar
  5. 5.
    Kumar S, Choudhary GR, Singh S, Prasad S, Singh SK, Bhansali A, Bhadada S, Dutta P(2015). Spectrum of retroperitoneal and genitourinary paraganglioma: Experience at a North Indian tertiary care center. Cent European J Urol68(4):421-427.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Gill, A. J. (2018). Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology, 72(1), 106-116.  https://doi.org/10.1111/his.13277 CrossRefPubMedGoogle Scholar
  7. 7.
    Fishbein, L., Khare, S., Wubbenhorst, B., et al. (2015). Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nature Communications, 6(6140).  https://doi.org/10.1038/ncomms7140
  8. 8.
    Job, S., Draskovic, I., & Burnichon, N. (2018). Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clinical Cancer Research.  https://doi.org/10.1158/1078-0432.CCR-18-0139 CrossRefGoogle Scholar
  9. 9.
    Kimura, N., Takayanagi, R., Takizawa, N., Itagaki E., Katabami T., Kakoi N., Rakugi H., Ikeda Y., Tanabe A., Nigawara T., Ito S., Kimura I., Naruse M., Phaeochromocytoma Study Group in Japan (2014). Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocrine-Related Cancer, 21(3), 405-414.  https://doi.org/10.1530/erc-13-0494 CrossRefPubMedGoogle Scholar
  10. 10.
    Koh, J., Ahn, S. H., Kim, H., Kim B.J., Sung T.Y., Kim Y.H., Hong S.J., Song D.E., Lee S.H. (2017). Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. Plos One, 12(11).  https://doi.org/10.1371/journal.pone.0187398 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PathologyUniversity of WashingtonSeattleUSA
  2. 2.Department of Laboratory MedicineUniversity of WashingtonSeattleUSA
  3. 3.SeattleUSA

Personalised recommendations